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Neurobiology of Disease
Inhibition of AMP-Activated Protein Kinase Signaling
Alleviates Impairments in Hippocampal Synaptic Plasticity
Induced by Amyloid 
TaoMa,1 Yiran Chen,1 Valerie Vingtdeux,2Haitian Zhao,2 Benoit Viollet,3,4,5 Philippe Marambaud,2 and Eric Klann1
1Center for Neural Science, New York University, New York, New York 10003, 2Litwin-Zucker Research Center for the Study of Alzheimer’s Disease, The
Feinstein Institute for Medical Research, Manhasset, New York 11030, 3Institut Cochin, INSERM U1016, Paris 75014, France, 4CNRS, UMR 8104, Paris
75014, France, and 5Universite´ Paris Descartes, Sorbonne Paris Cite´, Paris 75014, France
The AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that is activated in response to low-energy states to coordinate multiple
signaling pathways tomaintain cellular energy homeostasis. Dysregulation of AMPK signaling has been observed in Alzheimer’s disease
(AD), which is associatedwith abnormal neuronal energymetabolism. In the current studywe tested the hypothesis that aberrant AMPK
signaling underlies AD-associated synaptic plasticity impairments by using pharmacological and genetic approaches. We found that
amyloid  (A)-induced inhibition of long-term potentiation (LTP) and enhancement of long-term depression were corrected by the
AMPK inhibitor compound C (CC). Similarly, LTP impairments in APP/PS1 transgenic mice that model AD were improved by CC
treatment. In addition, A-induced LTP failure was prevented in mice with genetic deletion of the AMPK 2-subunit, the predominant
AMPK catalytic subunit in the brain. Furthermore, we found that eukaryotic elongation factor 2 (eEF2) and its kinase eEF2K are key
downstream effectors that mediate the detrimental effects of hyperactive AMPK in AD pathophysiology. Our findings describe a previ-
ously unrecognized role of aberrant AMPK signaling in AD-related synaptic pathophysiology and reveal a potential therapeutic target
for AD.
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Introduction
Alzheimer’s disease (AD) incidence has been rising consistently
with an aging population, potentially becoming a global threat to
public health (Querfurth and LaFerla, 2010; Holtzman et al.,
2011). Meanwhile, the lack of effective interventions for AD sug-
gests that the development of therapeutics will require novel
targets based on the identification of aberrant molecular mecha-
nisms underlying AD-related pathophysiology.
One of the signaling molecules that could be a therapeutic
target for AD is the AMP-activated protein kinase (AMPK).
Mammalian AMPKs are heterotrimeric complexes composed of
a catalytic -subunit encoded by either the 1 or 2 gene, and
regulatory - and -subunits. AMPK is activated by either bind-
ing of AMP with the -subunit or phosphorylation of the
-subunit at Thr172; the latter is quantitatively more important
for enzymatic activity (Hardie, 2004). AMPK is a key regulator of
cellular energy homeostasis, which is activated in response to
low-energy states (Hardie et al., 2012), and ADhas been linked to
abnormalities in neuronal energy metabolism (Lin and Beal,
2006). In addition, AMPK is activated by various types of cellular
stress that deplete ATP such as oxidative stress, which has been
implicated in AD pathology (Lin and Beal, 2006; Ma and Klann,
2012). Indeed, it has been reported that AMPK activity, as evalu-
ated by phosphorylation of Thr172, is robustly upregulated in
postmortem AD brains (Vingtdeux et al., 2011). Furthermore,
suppression of AMPK activity either pharmacologically or genet-
ically has been shown to exert neuroprotective effects in cerebral
ischemia (McCullough et al., 2005; Li et al., 2007; but see
Kuramoto et al., 2007).
AMPK also regulates protein synthesis, which plays a critical
role in consolidating long-lasting synaptic plasticity and long-
term memory (Klann and Dever, 2004; Costa-Mattioli et al.,
2009), and dysregulated protein synthesis recently was impli-
cated in AD pathogenesis (Ma et al., 2013). Of note, it was shown
that AMPK activity is important in maintaining protein
synthesis-dependent forms of synaptic plasticity (Potter et al.,
2010). Previous work, mainly in non-neuronal systems, has es-
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tablished that AMPK inhibits translation through at least two
mechanisms: (1) phosphorylation of TSC2, which results in in-
hibition of the mammalian target of rapamycin complex 1
(mTORC1) pathway (Hoeffer and Klann, 2010) and (2) phos-
phorylation and activation of eukaryotic elongation factor 2 ki-
nase (eEF2K), which subsequently phosphorylates and inhibits
the activity of eEF2, thereby turning off the elongation step in
translation (Horman et al., 2002; Hardie, 2004).
AD has been described as a disease of “synaptic failure” (Sel-
koe, 2002; Tanzi, 2005) and recently it was demonstrated that
dendritic spine loss associated with amyloid  (A) synaptotox-
icity is prevented by inhibitingAMPK signaling (Mairet-Coello et
al., 2013). However, direct evidence linking AD-associated syn-
aptic plasticity impairments and aberrant AMPK signaling has
yet to be demonstrated. Herein, using pharmacological and ge-
netic approaches, we directly tested the hypothesis that aberrant
AMPK signaling underlies AD-associated synaptic dysfunction.
Our findings reveal a previously unrecognized signalingmodule in-
volved in AD pathogenesis and thus, novel therapeutic targets for
this and other neurodegenerative diseases that result in dementia.
Materials andMethods
Mice. All mice (C57BL/6) were housed in the Transgenic Mouse Facility
of NewYorkUniversity, compliant with theNIHGuide for Care andUse
of Laboratory Animals. The facility is kept on a 12 h light/dark cycle, with
a regular feeding and cage-cleaning schedule. Bothmale and femalemice
were used for all experiments. APP/PS1(APPswe PSEN1dE9) transgenic
mice were purchased from the The Jackson Laboratory (Jankowsky et al.,
2001). AMPK 2 knock-out (KO) mice were generated as described
previously (Viollet et al., 2003b). All genotypes were determined by PCR.
Western blots of postmortemAD brain samples. For AMPK experiments
(Fig. 1A), soluble protein extracts from brain sections were provided by
the late Dr. Mark Smith from CaseWestern Reserve University. Samples
were collected and prepared in accordance with the institution’s Institu-
tional Review Board-approved protocols as described previously (Bonda
et al., 2010). Briefly, brain sections fromAD (n 4; age 72–89 years) and
control (n 3; age 65–86 years) were homogenized in 10 volume of lysis
buffer equipped with protease and phosphatase inhibitors (50 mM Tris-
HCl, pH7.6, 0.02% sodiumazide, 0.5% sodiumdeoxycholate, 0.1%SDS,
1%Nonidet P-40, 150 mMNaCl, 1 mM phenylmethylsulfonyl fluoride, 1
mg/ml aprotinin, 2 mg/ml antipain, and 1 mM sodium orthovanadate).
Twentymicrograms of soluble protein extracts were prepared frombrain
samples and standard Western blotting techniques were used as de-
scribed below. For eEF2 experiments (Fig. 5B), AD (Braak stages V–VI)
and age-matched normal control cases were obtained from the Albert
Einstein College of Medicine human brain bank (Bronx, NY). Brain
samples were from themid-temporal cortex. Samples were homogenized
and sonicated in Tris-buffered saline containing 2% SDS and 1 Com-
plete protease inhibitor mixture (Roche Applied Science) and centri-
fuged at 100,000  g for 1 h at 4°C. The resulting supernatants were
analyzed by Western blotting for the indicated proteins.
Immunohistochemistry on postmortem AD brain samples. Paraffin-
embedded hippocampal sections of postmortem human brain samples
were obtained from one control and three AD patients, Braak stage 6.
Tissue was obtained from the Albert Einstein College of Medicine brain
bank. Five micrometer thick sections of formalin-fixed, paraffin-
embedded brain tissue samples were immunostained with rabbit poly-
clonal antibodies directed against phospho-Thr-172 of AMPK
(p-AMPK; Abcam; 1:200 dilution) as previously described (Vingtdeux et
al., 2011). Briefly, the sections were deparaffinized by immersion in xy-
lene and hydration through graded ethanol solutions. Antigen recovery
was performed by incubating the slides for 30 min at 70°C in 10 mM
citrate buffer, pH 6.0. Endogenous peroxidase activity was inhibited by
incubation in 3% hydrogen peroxide and 0.25% Triton X-100 in Tris-
buffered saline (TBS) for 30 min at room temperature (RT), after which
slides were washed in TBS containing 0.05% Triton X-100 (TBS-T) and
blocked in 5%normal goat serum, 1mg/ml BSA, and 1mMNaF inTBS-T
for 1 h at RT. Sections then were incubated in the presence of primary
antibodies diluted in TBS-T containing 1% normal goat serum, 1 mg/ml
BSA,and1mMNaFovernightat4°C inahumidifiedchamber.Afterwashing
the sections were incubatedwith biotin-coupled, goat anti-rabbit secondary
antibodies (1:1000 dilution; Southern Biotech) before incubation with
streptavidin-horseradish peroxidase (1:1000 dilution; Southern Biotech)
and visualization with diaminobenzidine tetrahydrochloride.
Western Blots and antibodies used for mouse experiments. Lysates were
prepared as described previously (Banko et al., 2005). Equal amounts of
protein from each sample were loaded on 4–12% Tris-glycine SDS-
PAGE (Invitrogen) gels. After transfer, membranes were blocked for at
least 30 min at room temperature with blocking buffer [5% nonfat dry
milk in TBS containing 0.1%Tween 20 (TBS-T)], then probed overnight
at 4°C using the following primary antibodies (at dilutions of 1:1000,
unless otherwise specified): phospho-AMPK (Thr172) and AMPK (Cell
Signaling Technology), phospho-LKB1 (Ser428) and LKB1 (Cell Signal-
ing Technology), phospho-Akt (Ser473) and Akt (Cell Signaling Tech-
nology), phospho-eEF2 (Thr56) and eEF2 (Cell Signaling Technology),
actin (Sigma; dilution 1:10,000), GAPDH (Cell Signaling Technology;
dilution 1:10,000), phospho-mTOR (Ser2448) and mTOR (Cell Signal-
ing Technology), and eEF1A (Millipore). Densitometric analysis was
performed using Scion Image software.
Hippocampal slice preparation and electrophysiology. Acute 400 m
transverse hippocampal slices were prepared using a vibratome as de-
scribed previously (Ma et al., 2011). The slices were maintained at RT in
artificial CSF (ACSF) for at least 2 h before removal for experiments. For
electrophysiology experiments, monophasic, constant-current stimuli
(100 s) were delivered with a bipolar silver electrode placed in the
stratum radiatumof area CA3, and the fEPSPswere recorded in the stratum
radiatum of area CA1. LTP was induced with a high-frequency stimulation
(HFS) protocol consisting of two 1 s long 100 Hz trains, separated by 60 s,
delivered at 70–80% of the intensity that evoked spiked fEPSPs. LTD was
induced with 300 pulses of low-frequency stimulation (LFS) at 1 Hz.
Immunofluorescence and confocal microscopy. Slices were fixed over-
night in ice-cold 4% paraformaldehyde in PBS. Free-floating sections
were blocked with 10% normal goat serum, 1% BSA, and 0.1% Na azide
in PBS for2 h, and incubated with primary antibody phospho-AMPK
(Thr172; Santa Cruz Biotechnology. Alexa Fluor 568 secondary antibod-
ies (Invitrogen) were used. The sections were imaged using a Leica TCS
SP5 confocal microscope at 630. All parameters (pinhole, contrast, gain,
and offset) were held constant for all sections from the same experiment.
SUnSET protein synthesis assay. Proteins were labeled using a protocol
adapted from the SUnSET method (Schmidt et al., 2009). Hippocampal
slices were incubated with puromycin (1 g/ml) for 60 min throughout
the drug-treatment experiments. At the end of drug treatment slices were
harvested and frozen on dry ice. Area CA1 was microdissected and pro-
tein lysates were prepared forWestern blotting. Puromycin-labeled pro-
teins were identified using the mouse monoclonal antibody 12D10.
Protein synthesis levels were determined by taking total lane density in
the molecular weight range of 10–250 kDa.
Drug treatments.Drugs were prepared as stock solution in DMSO and
diluted into ACSF to its final concentration during experiments. The
final concentration of the drugs and the source were as follows: Com-
pound C (CC; 5 M; Calbiochem), NH125 (1 M; Calbiochem), A
(1–42; 500 nM; Tocris Bioscience). Incubation of hippocampal slices
with drugs was performed in either recording chambers or maintenance
chambers as needed.
Data analysis. Data are presented as mean SEM. Summary data are
presented as group means with SE bars. For comparison between two
groups, a two-tailed independent Student’s t test was used. For compar-
isons between multiple groups, an ANOVA was used followed by indi-
vidual post hoc tests when applicable. Error probabilities of p 0.05 were
considered statistically significant.
Results
Increased AMPK phosphorylation in AD brains
We first examined whether AMPK activity is altered in AD by
measuring phosphorylation at the Thr172 site on the -subunit
of AMPK. First,Western blot experiments on hippocampal slices
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from 10- to 12-month-old APPswe/PS1dE9 (APP/PS1) AD model
mice (Jankowsky et al., 2001) revealed an elevated phosphoryla-
tion of AMPK compared with wild-type littermates (Fig. 1A, top
left). Interestingly, this aberrant AMPK phosphorylation was not
observed in either cerebellum or prefrontal cortex of APP/PS1
mice (data not shown).We further examined hippocampal tissue
from postmortem human AD patients with Western blot and
immunohistochemical analyses and found that AMPK phos-
phorylation was increased compared with age-matched controls
(Fig. 1A, topmiddle,B). IncreasedAMPKphosphorylation in the
hippocampus of AD brains was manifested in degenerating neu-
rons and dystrophic neurites (Fig. 1B), two hallmarks of AD neu-
ropathology. We also treated wild-type mouse hippocampal
slices with exogenous A1–42 (500 nM) and observed a trend
toward increased levels of phosphorylated AMPK (Fig. 1A, top
right). To gain insight into the cellular distribution of AMPK
regulation in AD model mice, we performed immunofluores-
cence combined with confocal microscopy on hippocampal
slices. As revealed in Figure 1C, immunostaining for phosphory-
lated AMPKwasmarkedly higher in both the soma and dendrites
of stratum radiatum in hippocampal area CA1 of APP/PS1 mice
comparedwithwild-type littermates. These findings indicate that
AMPK phosphorylation is elevated in the hippocampus of AD
model mice and AD patients.
We further investigated the signaling pathways involved in the
AMPK dysregulation in AD model mice. Notably, we did not
detect a change in the phosphorylation levels of LKB1 (Fig. 1D),
which has been established as an upstream kinase for AMPK in
non-neuronal systems (Hardie, 2004). In contrast and consistent
with previous reports (Kovacic et al., 2003; Jo et al., 2011;Ma et
al., 2012), we observed decreased phosphorylation of Akt
(Ser473) in the hippocampus of APP/PS1 mice (Fig. 1D), consis-
tent with previous findings that Akt negatively regulates AMPK
resulting in decreased phosphorylation at Thr172 (Kovacic et al.,
2003; Hahn-Windgassen et al., 2005).These findings suggest that
AMPK activity is abnormally upregulated in AD brains.
Alterations in hippocampal synaptic plasticity induced by A
are rescued by the AMPK inhibitor CC
LTP is a form of synaptic plasticity that is widely believed to be a
cellular substrate for memory formation (Malenka, 2003). If
AMPK upregulation (hyperphosphorylation) plays a role in AD
pathogenesis, one would predict that blunting of AMPK activity
would alleviate AD-associated impairments in synaptic plasticity
Figure 1. Increased AMPK phosphorylation in Alzheimer’s disease. A, Western blot experiments showing AMPK phosphorylation (Thr172) in the hippocampus of APP/PS1 mice (left, n 9 for
WT and n 6 for APP/PS1), postmortemhumanADpatients (middle, n 4), and hippocampal slices treatedwith A (500 nM; right, n 6). Cumulative data are shown in the bar graph. Unpaired
independent t test; *p0.05.B, DAB staining (toluidineblue counterstaining) revealed increasedAMPKphosphorylation inareaCA1ofhippocampusofhumanADsamples; 20. Scalebar, 50m.
C, Immunofluorescence/confocal microscopy showing that phospho-AMPK (Thr172) was increased in area CA1 of hippocampal slices from APP/PS1 mice. Scale bar, 50 m. D, Western blot
experiments of hippocampal homogenates from APP/PS1 mice showing no change in LKB1 phosphorylation (Ser428; n 5), but decreased levels of Akt phosphorylation (Ser473; n 3).
Cumulative data are shown in bar graph. Unpaired independent t test; *p 0.05.
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that are a characteristic of AD pathophysiology (Rowan et al.,
2005; Ma and Klann, 2012). To test this notion, the AMPK an-
tagonist CC (5 M; Potter et al., 2010) was applied to hippocam-
pal slices in the presence of A1–42 (500 nM), which contains
ample A oligomers in the preparation method that was used
(Ma et al., 2010). Application of A itself to slices blocked LTP
induced by HFS (Fig. 2A,B). Although CC alone did not affect
LTP, it prevented A-induced LTP failure (Fig. 2A,B). Thus,
inhibiting AMPK prevents A-induced impairments in hip-
pocampal LTP.
A also is known to facilitate LTD, another form of hip-
pocampal synaptic plasticity (Li et al., 2009; Ma et al., 2012). We
first confirmed that in our conditions A facilitated LTD induc-
tion using a weak LFS protocol (see Materials and Methods),
which by itself did not elicit LTD (Fig. 2C,D). In comparison, in
slices treated with the AMPK inhibitor CC, the LTD enhance-
ment induced by A was absent (Fig. 2C,D). These results, cou-
pled with the results from the LTP experiments (Fig. 2A,B),
indicate that A-induced alterations in hippocampal synaptic
plasticity are prevented by inhibition of AMPK.
Impaired LTP in APP/PS1 ADmodel mice is alleviated by the
AMPK inhibitor CC
To further explore the role of AMPK hyperactivity in AD-related
impairments in hippocampal synaptic plasticity, we used slices
from APP/PS1 transgenic mice that model AD (Jankowsky et al.,
2001). Consistent with previous reports (Ma et al., 2011), hip-
pocampal LTP in APP/PS1 mice (10 to 12 months old) was in-
hibited (Fig. 3A,B). However, when slices from APP/PS1 mice
were treated with CC, LTP was significantly enhanced (Fig.
3A,B). Moreover, LTP was not altered in CC-treated slices from
wild-type mice (Fig. 3C). Defects in de novo protein synthesis
have been linked to synaptic dysfunction in APP/PS1mice (Ma et
al., 2013). To examine the effects of AMPK inhibition on de novo
protein synthesis in APP/PS1 mice, we performed SUnSET ex-
periments on hippocampal slices and observed that the levels of
newly synthesized proteins in area CA1 were increased by CC,
compared with the vehicle control groups (Fig. 3D,E). In addi-
tion,we also observed increased de novoprotein synthesis inwild-
type hippocampal slices treated with CC (Fig. 3D,E). These
results are consistent with the idea that hyperactive AMPK con-
Figure2. Hippocampal synaptic plasticity impairments caused byA are rescued byAMPK inhibitor CC.A, HFS-induced LTP in vehicle-treated hippocampal slices (open squares), but not in slices
treatedwithexogenousA (darkgray triangles). In contrast, CC (5M)enablednormal LTP induction in thepresenceofA (half-filled triangles). CCalonedidnot affect eitherHFS-inducedLTP (dark
gray diamonds) or baseline fEPSPs (open circles); n 5. B, Cumulative data showingmean fEPSP slopes 80min after HFS based on LTP experiments in A. Unpaired independent t test; *p 0.05.
C, A (500 nM)-facilitated LTD (dark gray triangles, n 11) induced by aweak HFS (1 Hz, 300 pulses), which normally did not induce LTD (open squares, n 7). In contrast, A did not induce LTD
in the presence of CC (5M; (ark gray circles, n 6). D, Cumulative data showing mean fEPSP slopes 50 min after LFS based on LTD experiments in C. Unpaired independent t test; *p 0.05.
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tributes to decreased de novo protein synthesis, which is associ-
ated with synaptic dysfunction in AD.
A-induced LTP failure is prevented by genetic removal of
the2-subunit of AMPK
Previous studies have revealed that both 1 and 2 isoforms of
AMPK are expressed inmouse brains, but that 2 is the predom-
inant catalytic subunit in neurons of the cortex and hippocampus
(Turnley et al., 1999). It is also noteworthy that AMPK2 knock-
out (KO) mice are protected from stroke damage, whereas
AMPK 1 KOmice are not (Li et al., 2007). Therefore, we exam-
ined A-induced impairments in LTP in mice that lack the 2-
subunit of AMPK (Viollet et al., 2003a,b). In hippocampal slices
derived fromAMPK 2 KOmice, LTP was comparable to that in
wild-type mice starting 30 min post-HFS (Fig. 4A). In contrast,
the A-induced LTP impairment observed in slices of wild-type
mice was prevented in slices from AMPK 2 KO mice (Fig. 4B–
D). These findings are consistent with the LTP studies using the
AMPK inhibitor (Figs. 2, 3) and provide further evidence of a
causal relationship between aberrant AMPK signaling and im-
pairments in synaptic plasticity associated with AD.
Inhibition of eEF2K activity rescues A-induced impairment
in LTP
De novo protein synthesis is critical for the consolidation of long-
term synaptic plasticity and memory (Klann and Dever, 2004;
Alberini, 2008). Of note, previous studies from non-neuronal
systems have indicated that AMPK activation inhibits protein
synthesis through either TSC2-mTORC1 or eEF2K–eEF2 signal-
ing pathways (Horman et al., 2002; Inoki et al., 2006). Thus, we
hypothesized that the effects of aberrant AMPK activity on AD-
related synaptic dysfunction would be mediated via the afore-
mentioned signaling pathways that control translation. In
correlation with AMPK activation (Fig. 1A,B), we observed a
marked increase in eEF2 phosphorylation (Thr56) in the hip-
pocampus of APP/PS1 mice (Fig. 5A). Notably, Western blots
performed on brain tissues from postmortem human AD pa-
tients also revealed a significant increase in eEF2 phosphorylation
compared with age-matched controls (Fig. 5B). Moreover, levels
of phosphorylated eEF2 were reduced in the hippocampus of
AMPK2 KO mice (Fig. 5C). These findings are consistent with
previous results from cell culture studies indicating that activa-
tion of AMPK results in eEF2 phosphorylation via eEF2K and
inhibition of protein synthesis (Horman et al., 2002; Browne et
al., 2004; Leprivier et al., 2013).Wedid not observe changes in the
phosphorylation of TSC2 (Ser1387) in hippocampal tissue from
APP/PS1mice (Fig. 5D) and removal of the2-subunit of AMPK
did not affect mTORC1 signaling as indicated by unaltered levels
of phosphorylated mTOR (Ser2448) and the expression of elon-
gation factor 1A (eEF1A; Tsokas et al., 2005; Fig. 5E). These re-
sults suggest that the activation of AMPK alters eEF2K-eEF2
signaling rather thanTSC2-mTORC1 signaling inAPP/PS1mice.
We proceeded to ask whether decreasing eEF2 phosphoryla-
tion could improve A-induced LTP deficits by using NH125, a
small molecule compound that is a selective and efficacious in-
hibitor of eEF2K (Arora et al., 2003). Notably, in hippocampal
slices treated with NH125 in the presence of A, HFS-induced
LTP was maintained. In contrast, NH125 alone did not impact
Figure 3. LTP impairments in APP/PS1 AD model mice are alleviated by the AMPK inhibitor CC. A, HFS-induced LTP was impaired in slices from APP/PS1 mice (gray triangles, n 7) and was
improved by CC treatment (dark gray circles, n 6). B, Representative fEPSP traces before and after HFS for LTP experiments shown in A. C, HFS-induced LTP was not altered in CC-treated slices
derived fromwild-type (WT)mice (gray circles, n 8).D, Representative blot showing CC treatment increased de novo protein synthesis (assayed by SUnSET) in area CA1 of hippocampus ofWT and
APP/PS1mice. E, Cumulative data showing CC treatment experiments; n 6. One-way ANOVA followed by post hoc Tukey test; *p 0.05.
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LTP (Fig. 5F–H). Collectively, these findings suggest that hyper-
phosphorylation of eEF2 via eEF2K activation plays a critical role
in mediating the effects of AMPK hyperactivation on AD-related
synaptic dysfunction.
Discussion
Present disease-modifying strategies for AD in clinical trials, such
as A antibody immunotherapy and gamma secretase inhibitors,
have met with limited success (Mangialasche et al., 2010). A bet-
ter understanding of the molecular and cellular mechanisms un-
derlying AD-associated synaptic dysfunction has the potential to
provide additional targets for novel therapeutics for this devas-
tating neurodegenerative disease. Numerous studies have dem-
onstrated that overproduction of reactive oxygen species (ROS)
and oxidative stress, presumably causing energy imbalance, play
an important role in AD-associated impairments of synaptic
function and memory formation (Lin and Beal, 2006; Massaad
and Klann, 2011; Ma and Klann, 2012). However, recent results
from human trials suggest it is difficult to remove ROS from
multiple sources with general antioxidants (Galasko et al., 2012).
In the current study, we directly examined the impact of inhibit-
ing AMPK, an energy sensor activated by ROS/oxidative stress,
on AD-associated synaptic dysfunction. We found that either
pharmacological or genetic inhibition of AMPK can prevent dis-
ruptions in synaptic plasticity caused by either exogenous A
exposure or displayed in APP/PS1 transgenic mice, consistent
with the observation that AMPK signaling is hyperactive in AD
brains. Furthermore, our studies revealed that eEF2K and its sub-
strate eEF2 are key downstream effectors that may mediate the
effects of hyperactive AMPK in AD pathophysiology, suggesting
that eEF2K is involved in AD pathogenesis and could be a poten-
tial novel therapeutic target.
Whether inhibition of AMPK activity would be either benefi-
cial or detrimental in AD is a subject under debate (Salminen et
al., 2011). On the one hand, activation of AMPK in response to
cellular stress is considered protective and has been established as
important in enhancing lifespan based on studies primarily from
non-mammalian systems (Apfeld et al., 2004; Mair et al., 2011);
the anti-aging effects of AMPK activation have been proposed to
protect against neurodegenerative diseases, includingAD (Doug-
las and Dillin, 2010). On the other hand, multiple lines of evi-
dence indicate that activation of AMPK could result in
detrimental outcomes and that restraining AMPK activity con-
fers neuroprotective effects in certain types of brain injury such as
stroke (McCullough et al., 2005; Li et al., 2007; Li and Mc-
Cullough, 2010). In light of the current findings in which we
demonstrated that blocking AMPK activity alleviates AD-
associated synaptic plasticity alterations, along with a recent
study showing that downregulation of AMPK signaling protects
Figure 4. A-induced LTP failure is prevented by genetic removal of the2-subunit of AMPK. A, Comparable LTP was induced by HFS in hippocampal slices from either wild-type (WT; open
squares, n 7) or AMPK2 KOmice (gray circles, n 7). B, HFS-induced LTP was inhibited by exogenous A (dark gray squares, n 5), but maintained in slices derived from AMPK2 KOmice
in the presence of A (gray triangles, n 5). C, Representative fEPSP traces before and after HFS for LTP experiments shown inA andB.D, Cumulative data showingmean fEPSP slopes 80min after
HFS based on LTP experiments in A and B. Unpaired independent t test; *p 0.05.
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against A-induced loss of synapses (Mairet-Coello et al., 2013),
we propose that the neuronal effects of AMPK activation during
stress are conditional and contingent on the phase and/or po-
tency of the specific cellular stress factors. In other words, activa-
tion of AMPK in response to a modest and transient type of
assault would likely be protective in restoring the homeostasis of
energy metabolism. However, during prolonged and/or severe
cellular stress that would occur in either late-stage aging or in
pathological conditions including ischemia or AD, the ability of
AMPK to balance energy homeostasis would be overwhelmed
and its detrimental effects would in turn be amplified, further
facilitating the damage caused by cellular stress. It should also be
noted that as a crucial signaling node, AMPK is connected to
many downstream effectors.
Consistent with the idea that prolonged activation of
AMPK results in detrimental effects in AD are the results of the
eEF2 experiments in the current study. AMPK activation leads
to the activation of eEF2K, which in turn phosphorylates and
inhibits the activity of eEF2, a translation factor that regulates
the elongation step of mRNA translation. Although a tran-
sient, initial shutdown of protein synthesis would normally
benefit cells by saving energy (from the energy-consuming
process of new protein synthesis) to cope with the stress insult,
prolonged and irreversible impairments in translational ca-
pacity would unavoidably hamper long-lasting synaptic plas-
ticity and memory formation because de novo protein
synthesis is essential for both processes (Richter and Klann,
2009).
Figure 5. Inhibition of eEF2K activity rescues A-induced impairments in LTP. A, Western blot demonstrating that levels of phosphorylated eEF2 (Thr56), but not total eEF2, were increased in
the hippocampus of APP/PS1 mice. Cumulative data are shown in the bar graph; n 8 for wild-type (WT), n 7 for APP/PS1. Unpaired independent t test; *p 0.05. B, Western blot
demonstrating that eEF2 phosphorylation at Thr56 was increased in postmortem human AD brain tissues compared with age-matched controls. Cumulative data are shown in the bar graph; n
5 for bothgroups.Unpaired independent t test; *p0.05.C,Westernblot experiments showing that levels of eEF2phosphorylationweredecreased inAMPK2KOmice. Cumulativedata are shown
in the bar graph; n 6. Unpaired independent t test; *p 0.05.D, Western blot experiments showing that levels of TSC2 phosphorylation (Ser1387) were not altered in hippocampus of APP/PS1
mice; n 6. Unpaired independent t test; p 0.05. E, Phosphorylation of mTOR (Ser2448) and expression of eEF1A were not affected in the hippocampus of AMPK2 KO mice. Blots shown are
representative of three independent experiments. F, A caused LTP failure (gray triangles, n 9) compared with normal LTP induction in slices treated with vehicle (open squares, n 9).
Treatment of hippocampal sliceswith the eEF2K inhibitor NH125 rescued A-induced LTP impairment (half-filled triangles, n 7), whereas NH125 alone did not alter LTP (gray diamonds, n 6).
G, Cumulative data showingmean fEPSP slopes 80min after HFS based on LTP experiments in F. Unpaired independent t test; *p 0.05.H, Representative fEPSP traces before and after HFS for LTP
experiments with A treatment in the presence of either NH125 or vehicle shown in F.
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In summary, the central status of AMPK as an energy metab-
olism master regulator makes it an attractive candidate for AD
therapy. However, for the same reason one should be extremely
cautious about either activating or inhibiting AMPK in patients
until a better understanding of the profound effects it may have
on molecular signaling and cellular functions involved in cogni-
tion are more fully delineated.
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